Zoonoses

Newtopia Announces Strong Outcome Results of Weight Loss Study During COVID-19 Pandemic

Retrieved on: 
Monday, June 28, 2021
Health sciences, COVID-19, Occupational safety and health, Public health, Zoonoses, Human body weight, Academic disciplines, Articles

TORONTO, June 28, 2021 /PRNewswire/ -Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU), a tech-enabled habit change provider focused on disease prevention, today announced the results of a weight loss study conducted by the Company on client outcomes during the COVID-19 pandemic.

Key Points: 
  • TORONTO, June 28, 2021 /PRNewswire/ -Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU), a tech-enabled habit change provider focused on disease prevention, today announced the results of a weight loss study conducted by the Company on client outcomes during the COVID-19 pandemic.
  • The average weight loss across participants was 4.2%, with a total combined loss of 35,833 pounds.
  • According to a recent study by the American Psychological Association, 42% of U.S. adults reported statistically significant weight gain during 2020.
  • For more information about Newtopia's Weight Loss Study, please visit the Resources section of Newtopia's website.

India COVID-19 Diagnostics Market Report 2020-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021
Biotechnology, Pharmaceutical, Health, Occupational safety and health, COVID-19, Public health, Zoonoses, Health, Articles

The "India COVID-19 Diagnostics Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India COVID-19 Diagnostics Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Indian government expanded the network of government laboratories designated to test samples of suspected COVID-19 cases to 920 laboratories.
  • The companies which are contributing to the growth of the Indian COVID-19 diagnostics market include Biogenix Inc. Pvt.
  • The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

Retrieved on: 
Monday, June 28, 2021
Health sciences, Health, Articles, COVID-19, Occupational safety and health, Public health, Zoonoses, COVID-19 vaccines, Clinical trials

TEL AVIV, Israel and RALEIGH, N.C., June 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva, ABC294640)[1].

Key Points: 
  • TEL AVIV, Israel and RALEIGH, N.C., June 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva, ABC294640)[1].
  • Phase 2 study data, opaganib's global 475-patient Phase 2/3 study in hospitalized patients with COVID-19 is fully enrolled and is expected to be completed in the coming weeks.
  • Preliminary results showed potent inhibition of both the Beta and Gamma variants by opaganib at non-cytotoxic doses.
  • This means we expect opaganib to similarly work against other emerging COVID-19 variants, including the Delta (Indian) variant.

Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission

Retrieved on: 
Thursday, June 24, 2021
Respiratory diseases, Animal diseases, Medical specialties, Occupational safety and health, Atypical pneumonias, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome

Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.

Key Points: 
  • Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.
  • "We are excited that our Brazilian clinical study has now met the minimum FDA-EUA requirements for our submission to secure serial testing approval," expressed Rob Fia, Therma Bright's CEO.
  • Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
  • Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs.

FDA issues Emergency Use Authorization for CovAb™ SARS-CoV-2 Ab Test, the oral fluid rapid test for SARS-CoV-2 antibodies

Retrieved on: 
Thursday, June 24, 2021
Medicine, Health sciences, Medical specialties, Antiviral drugs, COVID-19 drug development, Monoclonal antibodies, COVID-19, Public health, Zoonoses, Emergency Use Authorization, Development of COVID-19 tests, Viral disease testing

CovAb, the only oral fluid rapid, Pan Ig antibody test for Covid-19 gets FDA Emergency Use Authorization

Key Points: 
  • CovAb, the only oral fluid rapid, Pan Ig antibody test for Covid-19 gets FDA Emergency Use Authorization
    CovAb is the first and only rapid, oral fluid-based, point-of-care antibody test authorized by the FDA for use under an EUA.
  • In addition to being rapid and noninvasive, the CovAb test has sensitivity of 97.6% and specificity of 98.8%.
  • The CovAb test was developed based on Diabetomics' expertise in oral fluid and autoantibody diagnostics developed for its core service areas of diabetes and fetal-maternal disease.
  • The CovAb test is available for sale through Diabetomics' subsidiary COVYDx, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/fda-issues-emergency-use-authori...

DeepVerge plc: Microtox® PD claims world first live data alerts of SARS-Cov-2 in wastewater treatment plants

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Public health, COVID-19, Occupational safety and health, Zoonoses, Severe acute respiratory syndrome, Wastewater-based epidemiology

YORK, England, June 24, 2021 /PRNewswire/ -- DeepVerge (LSE: DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.

Key Points: 
  • YORK, England, June 24, 2021 /PRNewswire/ -- DeepVerge (LSE: DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.
  • "The successful completion of the Phase 3 field trials clearly demonstrates the capability and value of Microtox PD to identify dangerous pathogens, including SARS-CoV-2, in real-time.
  • By establishing a permanent anonymised mass surveillance of wastewater, DeepVerge claims a world first real-time defence against this global pandemic.
  • The installation of Microtox PD wastewater units will enable live data to simultaneously identify the source of COVID-19 cases as well as identify COVID-19 clusters with the ability to indicate the size of each cluster.

LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

 LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

Draper Delivers a First by Infecting Lung-on-Chip with Wildtype SARS-CoV-2 Virus

Retrieved on: 
Wednesday, June 23, 2021
Coronaviridae, Medical specialties, Zoonoses, Medicine, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome, Virus, Viral disease, Coronavirus

"In SARS-CoV-2 research, organ-on-chip is emerging as a powerful method for scientists to assess the potential effects of drugs in humans.

Key Points: 
  • "In SARS-CoV-2 research, organ-on-chip is emerging as a powerful method for scientists to assess the potential effects of drugs in humans.
  • "The door is now open for using naturally circulating viruses to develop and screen therapies for COVID-19 using the best method availableorgan-on-a-chip."
  • In the study, the researchers investigated viral infection kinetics of the SARS-CoV-2 virus in the PREDICT96-ALI platform in a BSL-3 laboratory environment.
  • Results with naturally occurring, or wildtype, virus are more relevant to the infection and replication process that causes disease in humans.

Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment

Retrieved on: 
Wednesday, June 23, 2021
Medical specialties, Medicine, Virology, Clinical medicine, Immunology, Vaccination, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Zoonoses, Immunity, Variants of SARS-CoV-2, Infection

QBKPN restores and enhances innate immune function, the bodys first line of defense against all viral infections.

Key Points: 
  • QBKPN restores and enhances innate immune function, the bodys first line of defense against all viral infections.
  • By restoring innate immunity, QBKPN is designed to contain and clear viral infection before it has an opportunity to spread.
  • As such, there is a risk that vaccine efficacy could be lost as new SARS-CoV-2 variants arise.
  • For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com .